Community-acquired Bacterial Pneumonia Treatment

Community-acquired Bacterial Pneumonia Treatment Market

  • HC-6349
  • 4.9 Rating
  • 220 Pages
  • Upcoming
  • 87 Reviews
  • Docx PDF Excel PPT
raksha

Author :

Raksha Sharma

Vineet

Fact-checked by :

Vineet Pandey

Vishal

Editor :

Vishal Golekar

Community-acquired Bacterial Pneumonia Treatment Market Outlook 2032 

The global Community-acquired bacterial pneumonia treatment market size was USD 5.5 Billion in 2023 and is likely to reach USD 9.5 Billion by 2032, expanding at a CAGR of 6.2% during 2024–2032. The market growth is attributed to the increasing prevalence of community-acquired bacterial pneumonia and increasing R&D activities and drug discoveries.

The global prevalence of chronic obstructive pulmonary disease (COPD) is rising as a result of aging populations, smoking, asthma, and COPD. However, COPD is the key cause of pneumonia. Several studies show that factors such as geography, weather conditions, and population characteristics influence the estimated global incidence of community-acquired pneumonia, which ranges from 1.5 to 14 cases per 1000 people per year. Furthermore, about 650 adults per 100,000 population, or 1.5 million individuals, are hospitalized annually in the US for community-acquired pneumonia (CAP).

Community-acquired pneumonia is one of the key causes of death and morbidity. Streptococcus pneumoniae is a major bacterial etiology of pneumonia, accounting for 23% of the global pneumonia burden with case fatality rates ranging from 14% to 30% in India.

Community-acquired Bacterial Pneumonia Treatment Market Outlook

Impact of Artificial Intelligence (AI) on the Community-acquired Bacterial Pneumonia Treatment Market

Artificial intelligence (AI) has a significant impact on the community-acquired bacterial pneumonia (CABP) treatment market. AI-powered chest X-ray analysis is expected to improve diagnosis and early intervention, while machine learning stratifies risk based on patient data. AI optimizes antibiotic use by analyzing local resistance patterns and suggesting effective treatments.

AI-powered chatbots provide 24/7 patient support and help predict complications, such as sepsis. AI also accelerates drug discovery and development by analyzing vast datasets. Additionally, AI reduces healthcare costs by enabling early diagnosis, targeted treatment, and optimized antibiotic usage, leading to reduced hospital stays and overall healthcare costs.

Community-acquired Bacterial Pneumonia Treatment Market Dynamics

Community-acquired Bacterial Pneumonia Treatment Market Dynamics


Major Drivers

Increasing instances of community-acquired bacterial pneumonia is driving the market. The disease is prevailing due to the increasing consumption of cigarettes and alcohol, rising environmental pollution, and the growing geriatric population. For instance,

  • According to an article published by the Centers for Disease Control and Prevention (CDC) in November 2022, about 40 million smokers in the US and a half million population of America die prematurely due to smoking or exposure to secondhand smoke.

Increasing R&D activities and drug discoveries is propelling the market. The rise of antibiotic-resistant bacteria has resulted in an urgent need for the development of new antibiotics that are effective against these pathogens. This, in turn, influenced the development of effective antibiotics.
 
Advancements in diagnostic technologies are driving the global market. Improvements in diagnostic techniques enable healthcare providers to identify causative bacterial pathogens accurately.

Existing Restraints

Generic competition increases as patents on existing antibiotics expire, leading to price erosion and decreased profitability for branded CABP treatments. The increasing generic competition hinders investment in research and development of new therapies, thereby restraining the market.

Stringent regulatory approval process for drugs is expected to impede the market during the projection period. The stringent regulatory approval process for new antibiotics and treatment modalities significantly creates barriers for new entrants and delays their market entry. Strict requirements for demonstrating safety and efficacy prolong the time to market new CABP treatments.

Emerging Opportunities

Rising development of novel antibiotics creates immense opportunities for key players competing in the market. The need for novel antibiotics with activity against multidrug-resistant bacterial strains is increasing. Thus, several pharmaceutical companies are investing in the research and development of new antibiotics or antibiotic combinations tailored to combat resistant pathogens.

Advancements in molecular diagnostics and genomic sequencing propel the market, as it enables the identification of specific bacterial pathogens and their antibiotic resistance profiles. Precision medicine approaches allow for targeted antibiotic therapy, minimizing the use of broad-spectrum antibiotics and reducing the risk of resistance.

Immunomodulatory therapies designed to enhance the host immune response against bacterial pathogens represent a promising avenue for CABP treatment. Immunotherapies including monoclonal antibodies and vaccines targeting specific bacterial antigens offer the potential for both prevention and treatment of CABP.

Scope of the Community-acquired Bacterial Pneumonia Treatment Market Report

The market report includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Community-acquired Bacterial Pneumonia Treatment Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2023

Historic Data

2017–2022

Forecast Period

2024–2032

Segmentation

Treatment Type (Antibiotics and Antivirals), Drug Class (Pleuromutilin, Cephalosporin, Glycylcycline, Oxazolidinone, and Ketolide), Route of Administration (Oral and Intravenous), and Distribution Channel (Hospital Pharmacies and Online Pharmacies)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast

Key Players Covered in the Report

Cubist Pharmaceuticals LLC; Cumberland Pharmaceuticals Inc.; Eagle Pharmaceutical Inc.; Eli Lilly & Company; GSK plc; Merck Sharp & Dohme Inc.; Pfizer Inc; Sanofi S.A.; Shionogi Inc.; and Teva Pharmaceuticals Industries Limited


Community-acquired Bacterial Pneumonia Treatment Market Segment Insights

Treatment Type Segment Analysis

Based on treatment type the community-acquired bacterial pneumonia treatment market is bifurcated into antibiotics and antivirals. The antibiotics segment is expected to expand at a significant growth rate during the projection period, as antibiotics are the first line of treatment against bacterial pneumonia. The development of broad-spectrum antibiotics and increasing focus on combination therapies is further driving the segment.

The antivirals segment is expected to grow at a rapid pace during the forecast period, owing to the increasing demand for antiviral drugs for the treatment of CABP, as they help to reduce flu virus spreading in the body. According to the National Library of Medicine, antiviral therapy reduces the mortality of patients with pH1N1 pneumonia. Moreover, the high prevalence of viral pneumonia following bacterial pneumonia infections through influenza virus, RSV, parainfluenza, metapneumovirus, or adenovirus is expected to drive the segment during the forecast period.

Community-acquired Bacterial Pneumonia Treatment Market Treatment Type

Drug Class Segment Analysis

On the basis of drug class, the global market is segregated into pleuromutilin, cephalosporin, penicillin, glycylcycline, oxazolidinone, and ketolide. The cephalosporin segment is anticipated to register a considerable CAGR in the coming years, owing to its high efficacy and safety profiles. Cephalosporins have demonstrated efficacy in treating various bacterial pathogens implicated in CABP, making them a preferred choice for empiric therapy, especially in regions where antibiotic resistance rates are low. Moreover, a favorable safety profile with a low incidence of adverse effects makes it suitable for a wide range of patient populations, thereby driving the segment.

The penicillin segment is expected to expand at a significant pace during the forecast period due to its high preference among patients. 875 mg/125 mg amoxicillin and clavulanate potassium tablet every 12 hours or one 500 mg/125 mg amoxicillin and clavulanate potassium tablet every 8 hours is the prescribed dose of the medicine for severe infections of the respiratory tract in adults. Furthermore, the penicillin class of drugs is given to outpatients with comorbidities, such as chronic heart, chronic lung, and chronic renal disease, thereby propelling the segment. 

Route of Administration Segment Analysis

On the basis of route of administration, the community-acquired bacterial pneumonia treatment market is segmented into oral and intravenous. The oral segment is expected to register a robust growth rate during the forecast period, owing to ease of administration of oral drugs and no skilled professionals required. Additionally, the higher convenience of taking a pill at home and the lesser cost of oral medication than intravenous is driving the segment.

Community-acquired Bacterial Pneumonia Treatment Market Route of administration

Distribution Channel Segment Analysis

Based on distribution channel, the global market is divided into hospital pharmacies and online pharmacies. The hospital pharmacies segment is expected to hold a large share of the market during the projection period, owing to a high rate of hospitalization of CABP patients.

The high safety of drugs obtained from hospital pharmacies is boosting the segment. The presence of skilled pharmacists in hospital pharmacies provide guidance about medication administration, thereby reducing possible side effects associated with medicines Furthermore, high expertise and guidance on the dosage and related side effects make hospital pharmacies a preferred place to buy medicine.

Regional Analysis

In terms of region, the global community-acquired bacterial pneumonia treatment market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. Middle East & Africa is expected to dominate the market during the forecast period, owing to the increasing technological advancements in the healthcare and development of advanced antibiotics in the region. Furthermore, the demand for new and effective treatments is rising in the region, which drives the regional market. The increasing number of CABP cases is causing acute lung infections in the population of the region. For instance,

  • According to a report published by the Indian Journal of Medical Research in 2020, nearly 2.4 million deaths occur among all ages due to lower respiratory tract infections (LRTIs). In 2016, about 197.05 million instances of pneumococcal pneumonia were reported worldwide and thus represented the key cause of lower respiratory tract infection morbidity and mortality.

North America is expected to hold a large share of the market during the forecast period. The market growth is attributed to the increasing R&D activities for the development of novel therapies. The presence of key players in this region, including Melinta Therapeutics, Wakunaga Pharmaceutical, Forest Pharmaceuticals, and Pfizer, is striving to develop effective therapeutic options for CABP, which is expected to drive the market during the forecast period. Moreover, the growing prevalence of CABP in the region fuels the regional market. 

Community-acquired Bacterial Pneumonia Treatment Market Region

Segments

The community-acquired bacterial pneumonia treatment market has been segmented on the basis of

Treatment Type

  • Antibiotics
  • Antivirals

Drug Class

  • Pleuromutilin
  • Cephalosporin
  • Glycylcycline
  • Oxazolidinone
  • Ketolide

Route of Administration

  • Oral
  • Intravenous

Distribution Channel

  • Hospital Pharmacies
  • Online Pharmacies

Region

  • Asia Pacific

  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Cubist Pharmaceuticals LLC
  • Cumberland Pharmaceuticals Inc.
  • Eagle Pharmaceutical Inc.
  • Eli Lilly & Company
  • GSK plc
  • Merck Sharp & Dohme Inc.,
  • Pfizer Inc.
  • Sanofi S.A.
  • Shionogi Inc.
  • Teva Pharmaceuticals Industries Limited

Competitive Landscape

Key players competing in the global community-acquired bacterial pneumonia treatment market include Cubist Pharmaceuticals LLC; Cumberland Pharmaceuticals Inc.; Eagle Pharmaceutical Inc.; Eli Lilly & Company; GSK plc; Merck Sharp & Dohme Inc.; Pfizer Inc; Sanofi S.A.; Shionogi Inc.; and Teva Pharmaceuticals Industries Limited

These companies adopt development strategies including mergers, acquisitions, partnerships, collaboration, product launches, and production expansion to expand their consumer base worldwide. For instance,

  • In January 2023, Paratek Pharmaceuticals, Inc., a biopharmaceutical firm, added its intravenous formulation of NUZYRA (omadacycline) to the National Reimbursement Drug List of China for treating community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. NUZYRA, an oral and intravenous antibiotic, is approved in the US for treating bacterial pneumonia and skin and skin structure infections.

    Community-acquired Bacterial Pneumonia Treatment Market Key Players

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Community-acquired Bacterial Pneumonia Treatment Market Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Community-acquired Bacterial Pneumonia Treatment Market Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Community-acquired Bacterial Pneumonia Treatment Market Market - Supply Chain
  4.5. Global Community-acquired Bacterial Pneumonia Treatment Market Market Forecast
     4.5.1. Community-acquired Bacterial Pneumonia Treatment Market Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Community-acquired Bacterial Pneumonia Treatment Market Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Community-acquired Bacterial Pneumonia Treatment Market Market Absolute $ Opportunity
5. Global Community-acquired Bacterial Pneumonia Treatment Market Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Community-acquired Bacterial Pneumonia Treatment Market Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Community-acquired Bacterial Pneumonia Treatment Market Demand Share Forecast, 2019-2026
6. North America Community-acquired Bacterial Pneumonia Treatment Market Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Community-acquired Bacterial Pneumonia Treatment Market Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Community-acquired Bacterial Pneumonia Treatment Market Demand Share Forecast, 2019-2026
7. Latin America Community-acquired Bacterial Pneumonia Treatment Market Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Community-acquired Bacterial Pneumonia Treatment Market Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Community-acquired Bacterial Pneumonia Treatment Market Demand Share Forecast, 2019-2026
8. Europe Community-acquired Bacterial Pneumonia Treatment Market Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Community-acquired Bacterial Pneumonia Treatment Market Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Community-acquired Bacterial Pneumonia Treatment Market Demand Share Forecast, 2019-2026
9. Asia Pacific Community-acquired Bacterial Pneumonia Treatment Market Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Community-acquired Bacterial Pneumonia Treatment Market Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Community-acquired Bacterial Pneumonia Treatment Market Demand Share Forecast, 2019-2026
10. Middle East & Africa Community-acquired Bacterial Pneumonia Treatment Market Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Community-acquired Bacterial Pneumonia Treatment Market Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Community-acquired Bacterial Pneumonia Treatment Market Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Community-acquired Bacterial Pneumonia Treatment Market Market: Market Share Analysis
  11.2. Community-acquired Bacterial Pneumonia Treatment Market Distributors and Customers
  11.3. Community-acquired Bacterial Pneumonia Treatment Market Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)

Purchase Premium Report